Receptos Announces Appointment of Mary Lynne Hedley, Ph.D. as Director
15 April 2014 - 6:56AM
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company
developing therapeutic candidates for the treatment of immune and
metabolic diseases, today announced the appointment of Mary Lynne
Hedley, Ph.D. as a director of Receptos. Dr. Hedley will serve as a
Class I director with a term of office expiring and to be
renewed at the 2014 annual meeting of stockholders. Dr. Hedley
will also serve as a member of the Board's Nominating and Corporate
Governance Committee.
Dr. Hedley has served as president of Tesaro, Inc. and as a
member of its Board of Directors since co-founding Tesaro in March
2010. From July 2009 to February 2010, Dr. Hedley served as
executive vice president of operations and chief scientific officer
of Abraxis BioScience, Inc., a biotechnology company. Dr. Hedley
served as executive vice president of Eisai Corporation of North
America from January 2008 until July 2009, following Eisai Co.
Ltd.'s acquisition of MGI Pharma, Inc. in January 2008. Dr. Hedley
served in various positions at MGI Pharma from 2004 through its
acquisition in January 2008, most recently as executive vice
president and chief scientific officer. Prior to that, Dr. Hedley
co-founded and served as the president and chief executive officer
of Zycos, Inc., a biotechnology company, which was acquired by MGI
Pharma in 2004. Prior to co-founding Zycos, Dr. Hedley completed
two consecutive postdoctoral fellowships at Harvard University and
earned a B.S. in microbiology from Purdue University and a Ph.D. in
Immunology from the University of Texas, Southwestern Medical
Center. She also currently sits on the board of Youville Place.
Bill Rastetter, Chairman of the board of directors of Receptos,
said, "We are pleased to welcome Mary Lynne to the Receptos Board
of Directors. Her operating and management experience in the life
sciences industry, as well as her deep scientific background,
provide unique qualifications and skills which we believe will be a
valuable asset to Receptos and we look forward to working with
her."
About Receptos
Receptos is a biopharmaceutical company developing therapeutic
candidates for the treatment of immune and metabolic diseases. The
Company's lead program, RPC1063, is a sphingosine 1-phosphate 1
receptor (S1P1R) small molecule modulator candidate for immune
indications, including relapsing multiple sclerosis (RMS) and
inflammatory bowel disease (IBD). The Company is also developing
RPC4046, an anti-interleukin-13 (IL-13) antibody for an
allergic/immune-mediated orphan disease, eosinophilic esophagitis
(EoE). Receptos has established expertise in high resolution
protein crystal structure determination, biology and drug discovery
for G-protein-coupled receptors (GPCRs).
CONTACT: Media and Investor Contact:
Graham K. Cooper
Chief Financial Officer, Receptos
(858) 652-5708
gcooper@receptos.com
RECEPTOS, INC. (NASDAQ:RCPT)
Historical Stock Chart
From Jun 2024 to Jul 2024
RECEPTOS, INC. (NASDAQ:RCPT)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about (MM) (NASDAQ): 0 recent articles
More News Articles